E Fund Management Co. Ltd. sells 22,135 shares of Cogent Biosciences, Inc. (NASDAQ:COGT)

E Fund Management Co. Ltd. reduced its position in shares of Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report) by 66.5% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 11,173 shares of the technology company’s stock after selling 22,135 shares during the quarter. E Fund Management Co. holdings. Ltd.’s holdings in Cogent Biosciences were worth $94,000 at the end of the most recent quarter.

Several other institutional investors have also recently added to or reduced their stakes in the company. Jump Financial LLC bought a new position in shares of Cogent Biosciences in the fourth quarter valued at about $147,000. Dynamic Technology Lab Private Ltd bought a new position in Cogent Biosciences in the 4th quarter valued at $70,000. Trexquant Investment LP boosted its stake in Cogent Biosciences by 88.3% in the fourth quarter. Trexquant Investment LP now owns 77,402 shares of the technology company’s stock worth $455,000 after buying an additional 36,294 shares in the last quarter. Capstone Investment Advisors LLC purchased a new position in Cogent Biosciences in the fourth quarter valued at $238,000. Finally, NEOS Investment Management LLC bought a new stake in shares of Cogent Biosciences in the fourth quarter valued at $76,000.

Analyst upgrades and downgrades

Several brokerages have recently issued reports on COGT. JPMorgan Chase & Co. cut their target price on shares of Cogent Biosciences from $22.00 to $19.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 7th. Wedbush restated a “neutral” rating and set a $11.00 target price (up from $10.00) on shares of Cogent Biosciences in a research report on Tuesday, September 3rd. HC Wainwright cut their price target on shares of Cogent Biosciences from $19.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, September 3rd. Needham & Company LLC restated a “buy” rating and issued a $18.00 price objective on shares of Cogent Biosciences in a research report on Wednesday, August 7th. Finally, Robert W. Baird raised their price objective on Cogent Biosciences from $8.00 to $10.00 and gave the company a “neutral” rating in a research report on Thursday, September 5th. . Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Moderate Buy” and a consensus price target of $14.67, based on data from MarketBeat.com.

Read the latest stock report on Cogent Biosciences

Cogent Biosciences Stock Performance

COGT opened at $10.90 on Friday. The company has a fifty day moving average price of $9.73 and a two hundred day moving average price of $8.27. The firm has a market cap of $1.19 billion, a PE ratio of -4.40 and a beta of 1.70. Cogent Biosciences, Inc. it has a 52-week low of $3.67 and a 52-week high of $12.14.

Cogent Biosciences (NASDAQ:COGT – Get Your Free Report ) last announced its quarterly earnings data on Tuesday, August 6th. The technology company reported ($0.59) EPS for the quarter, missing analysts’ consensus estimates of ($0.56) by ($0.03). During the same period last year, the company earned ($0.59) earnings per share. Stock analysts predict that Cogent Biosciences, Inc. will record -2.25 EPS for the current year.

About Cogent Biosciences

(Free report)

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations in the KIT tyrosine kinase receptor, including the KIT D816V KIT D816V mutation that causes systemic mastocytosis, as well as other KIT exon 17 mutations that are found . in patients with advanced gastrointestinal stromal tumors.

See Also

Want to see what other hedge funds hold COGT? Visit HoldingsChannel.com to get the latest 13F filings and insider trading for Cogent Biosciences, Inc. (NASDAQ:COGT – Free Report).

Get news and reviews for Cogent Biosciences Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Cogent Biosciences and related companies with MarketBeat.com’s FREE daily email newsletter.